Mckenna Grace paired her micro minidress with Sonia Petroff jewelry for an interview during "The Hunger Games: Sunrise on the Reaping" press run. The 20-year-old portrays Maysilee Donner and her sister Merrilee Donner in the movie. She has delivered several striking looks throughout the press run.
Mckenna Grace joined co-star Joseph Zada on the new episode of the Spanish talk show "La Revuelta." Styled by Molly ***** son, the "Gifted" actress accessorized with Sonia Petroff Swan Earrings. Crafted from brass with 24-carat gold overlay, the earrings wrapped around the ear in an ear-cuff silhouette.
The top arch resembled a slender, graceful swan neck ending in a downturned beak, while the base fanned out into a stylized wing. Further, brilliant Swarovski diamonds adorned the wings' feathers. A single ***** rous pearl sat right at the bend where the neck met the plumage.
Grace paired the beautiful earrings with the Sau Lee Caspian Jacquard Print Dress. The metallic gold minidress features a high Mandarin-style collar framing a keyhole chest cutout. The bodice hugged her torso and cinched at the waist before falling into a short hemline with a little side slit for ease of movement.
The metallic gold jacquard wove an ornate, textured surface pattern that caught light from every angle, echoing the opulence of the gilded jewelry. Meanwhile, the short hemline put her long legs on full display. She paired the dress with sheer black tights, elongating the leg line. Black slingback pumps completed her look. Together, the tights and the shoes created a streamlined vertical line.

#grace #Gold #mckenna #jacquard

Long Island mansion Oheka Castle will be sold to the highest bidder after its owner filed Chapter 11 bankruptcy
Taylor Swift filmed her "Blank ****** e" music video at the estate, riding horses through its formal gardens
Kevin Jonas, Joey Fatone, Curtis Martin and Megyn Kelly each celebrated weddings at the historic venue
America's second largest private residence, Oheka Castle, is heading to the auction block this October.
Completed in 1919, the Gilded Age residence was built by financier Otto Hermann Kahn to be used as a summer home. In the years since, the 109,000-square-foot, 127-room estate has become a wedding destination for celebrities. Kahn's own daughter, socialite Maud, became the castle's first bride when she walked down the aisle on June 15, 1920, according the castle's official website.

#oheka #long #island #chapter

Morgan Stanley met privately with Gilead Sciences (GILD) leadership at its 2026 Global Healthcare Conference this month, and the feedback strengthened the bank's positive view on the stock.
Morgan Stanley's biopharma team hosted a meeting and a management dinner with Gilead Chairman and CEO Daniel O'Day and Chief Commercial and Corporate Affairs Officer Johanna Mercier. According to a Morgan Stanley research note shared with me, the discussion reinforced its Overweight rating on Gilead and singled out one franchise as the biggest reason to stay positive.
Gilead trades around $150.89, up about 24% year to date and roughly 111% over five years. That kind of run in a biotech stock usually needs a catalyst, and Morgan Stanley points to HIV prevention. The bigger question for investors now is whether the new HIV prevention business built around Yeztugo can keep growing at the pace of the last few quarters.
Terence Flynn, a Morgan Stanley equity **** yst who covers Gilead and other healthcare stocks has held an Overweight rating on the stock since January 2025.
According to the note, Gilead management described the company as being at "an important inflection point, supported by what it views as the most robust portfolio in the company's history," with no patent expiring until 2036.

#gilead #healthcare #management #note

A-listers including Claire Danes, Noah Wyle and Kaley Cuoco stepped out to one of the hottest parties ahead of the Emmys: The Motion Picture & Television Fund's big, star-studded bash to raise funds and awareness for the organization.
The party, which was co-hosted by PEOPLE, took place at Pacific Design Center on September 13, 2026 in West Hollywood; it was the 20th annual event, held to raise money for the MPTF organization, which supports members of the entertainment industry in need. Stars from some of the biggest and most Emmy nominated shows on TV, including The Pitt, The Gilded Age, Abbott Elementary and Pluribus, mixed and mingled (and, in some cases, gave us an ER reunion that melted our hearts).
See the best photos from the party below.
01 of 20
Credit: Stefanie Keenan/Getty

#including #claire

Gilded and glamorous, Eva Longoria graced the red carpet at the Global Gift Gala Madrid 2026, held at the Casino de Madrid on Sept. 13 in Madrid. The actress' look was ethereal from the makeup to her gown.
The "Desperate Housewives" star was ethereal, clad in a high-shine gold gown consisting of a sleeveless high-neck bodice and a form-fitted construction. Longoria's chosen garment was seemingly crafted of a fabric affixed with teeny tiny sequins that caught the camera's flash wherever she turned. The dress was straight up and down, a silhouette with shape in the center before shooting straight down to the floor where the skirt pooled at her feet.
More from WWD
Eddie Borgo Reclaims His Icons at Nordstrom
EXCLUSIVE: Jessica McCormack Designs Sea-inspired Jewels for Design Firm L'Objet

#ethereal #high #straight #gilded

On August 13, a federal appeals court ruled in favor of Gilead Sciences, Inc. (NASDAQ:GILD), upholding a preliminary injunction that bars the defendants from importing or facilitating the sale of foreign-market Gilead-branded medications in the US. The US Court of Appeals for the Fourth Circuit found that the differences between Gilead's HIV medication for the US market and the foreign versions being imported were "material, not theoretical." The controversy began in December 2024 when Gilead Sciences, Inc. (NASDAQ:GILD) filed suit against a number of companies, including third-party administrator Meritain Health, pharmacy benefit manager ProAct, and pharmacies Rx Valet and Advanced Pharmacy, alleging illegal imports of its best-selling HIV drug Biktarvy.
The dispute dates back to December 2024, when Gilead Sciences, Inc. (NASDAQ:GILD) sued a group of companies, including third-party administrator Meritain Health, pharmacy benefit manager ProAct, and pharmacies Rx Valet and Advanced Pharmacy, alleging illegal imports of its top-selling HIV drug Biktarvy. The lawsuit arose from a specific instance in which a patient in Maryland received the medicine in the mail from Turkey, with label instructions written in Turkish.
A federal district court in Baltimore ruled in Gilead's favor and ordered a preliminary injunction, determining that the company was likely to succeed on its Lanham Act trademark violation and unfair competition arguments. As the case continued, the injunction was increased to include new sellers like CanaRx, ElectRx, and ScriptSourcing. The defendants filed an appeal with the Fourth Circuit, and the district judge declined to suspend the injunction while the appeal was pending, thus the import restriction has been in effect the entire time. The recent ruling maintains the order rather than overturning it.
In court documents, Rx Valet stated that the Turkish-sourced Biktarvy was chemically identical to the US version, which was offered at a significantly higher price. Meritain, for its part, said that it has never supported getting non-FDA-approved pharmaceuticals from outside the US and denies the claims, despite being named as a defendant.
The Fourth Circuit rejected the defendants' main argument that the imported and domestic versions of Biktarvy are interchangeable. The court's judgment that the two versions differ materially, not just in packaging or labeling, but also in the quality-control protocols that each version goes through before reaching a patient, challenges the basic argument that these alternative funding programs have used to support their business model.

#gild

Taylor Swift and Travis Kelce's new Ohio home is already drawing more than celebrity interest. The couple's reported plans for the property have put them at odds with some nearby residents, turning a private home project into a local disagreement.
The issue centers on a proposed fence and concerns over how it could affect the surrounding views.
The reported disagreement involves the $5.35 million Gilded Age mansion Swift and Kelce quietly purchased in Bratenahl, Ohio, a Lake Erie waterfront village just outside Kelce's hometown of Cleveland Heights.
According to celebrity gossip platform Deuxmoi, Kelce finalized the purchase in March, with the property spanning 3.5 acres and roughly 21,000 square feet.
The couple is reportedly planning to install a fence around the property for security, but the proposal has not been welcomed by everyone nearby. A source cited by Deuxmoi said some neighbors "aren't exactly thrilled" because they believe the fence could interfere with their lake views.

#ohio #deuxmoi #celebrity

Gilead Sciences (NASDAQ: GILD) has no major concerns about its HIV franchise until the next decade. That hasn't kept the pharmaceutical company from preparing for the loss of exclusivity for its legacy HIV therapies. Gilead has spent heavily on its pipeline, and that's paying off.
The company has received three Food and Drug (FDA) approvals over the past four months, and not coincidentally, its shares are up more than 21% so far this year, nearly doubling the S&P 500 index's rise. The most recent approval was on Aug. 27 for Bixlenvo as a daily pill to treat virologically suppressed adults with HIV.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Prior to that, on June 24, Trodelvy received two new approvals to treat triple-negative breast cancer. On May 22, the FDA granted Hepcludex accelerated approval to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis.
Despite the stock's rise and all the good news on the pipeline front, Gilead may be underrated. There are three reasons why I feel that is the case.

#gilead #NVIDIA #three

On one hand, Heidi O'Neill has her work cut out for her as chief executive officer of Lululemon Athletica Inc.
Second-quarter sales fell 4 percent to $2.4 billion with 12 percent comparable sales drop in the Americas and a 3 percent decline internationally.
More from WWD
Victoria's Secret Sales Jump 10% in Q2, Giving the Brand Momentum Ahead of Runway Show
Ermenegildo Zegna's H1 Operating Profit Boosted by Zegna Brand's Margins

#second #secret

Foster City, California-based Gilead Sciences, Inc. (GILD) discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States and internationally. The company has a market cap of $185.9 billion and provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo for the treatment of HIV-1 infection in patients, as well as other related drugs.
Companies with a market cap of $10 billion or more are typically referred to as "large-cap stocks." GILD fits perfectly into that category, with its market cap exceeding this threshold and reflecting its substantial size and influence in the general drug manufacturers industry.
Nvidia CEO Jensen Huang Says His $3.5 Billion MediaTek Deal Is 'Not Circular' Because 'They Do Their Own Business'
Strategy's Strategy Appears to Have Failed, and the Outlook of MSTR Stock Is Unfavorable
A Potential ******* eX Deal Could Meaningfully Accelerate Growth for Technip Stock

#gild #deal #Stock #sciences

On September 3, Ermenegildo Zegna Group (NYSE:ZGN) reported first-half revenues of €987.3 million, up 6.4% year over year and 9.3% on an organic basis. Direct-to-consumer sales did nearly all the work, climbing 15.8% organically and now making up 86% of branded revenue. But headline profit told a rougher story, sliding to €28.4 million from €47.9 million a year earlier. The gap between a business growing almost everywhere that matters and a bottom line moving the other direction is what investors now have to untangle.
The clearest strength in the first half of 2026 is how much of Zegna's growth is coming from channels it controls directly. Direct-to-consumer revenue grew 12.1% as reported and 15.8% organically, while the Group deliberately shrank its wholesale business by 14.6% as it keeps trimming third-party accounts. The Zegna segment, which houses the flagship ZEGNA brand along with Textile, generated €724.3 million in revenue, up 9.7% year over year, with the ZEGNA brand itself growing 13.9% organically to €634.6 million. That segment's Adjusted EBIT Margin rose 50 basis points to 14.8%, driven by higher sales per square meter and better sell-through in its own stores.
Group-wide Adjusted EBIT rose to €74.5 million from €68.7 million, pushing the margin to 7.5%. The balance sheet moved in the right direction too, with the net cash surplus climbing to €59.6 million at June 30 from €52.1 million at December 31, 2025. Free cash flow flipped to a positive €19.2 million, compared with a negative €23.1 million a year earlier, helped by stronger operating cash flow and tighter working capital management. Even Tom Ford Fashion, still unprofitable, cut its Adjusted EBIT loss to €12.1 million from €19.4 million, a sign the newer brand is moving toward breakeven rather than away from it.
The drop in profit isn't just optics. H1 2025's €47.9 million figure included a €27.8 million non-cash gain from remeasuring non-controlling interest put option liabilities, a boost that didn't repeat this year. On top of that, the effective tax rate jumped to 38.8% from 29.6%, and the combined swing in financial expenses and foreign exchange moved to a negative €22.7 million from a positive €6.0 million. Together, those items explain most of the gap between a profit margin of 2.9% this year and 5.2% last year, even as operating profit itself improved to €68.5 million from €61.3 million.
Thom Browne is the segment causing the most concern. Revenue there fell 4.9% year over year to €123.1 million, and Adjusted EBIT swung to a loss of €8.3 million from a profit of €4.5 million, which the company attributed to foreign exchange pressure and investment in shifting the brand toward a retail-first model. Capital expenditure also climbed to €64 million from €54 million, largely tied to a new shoe production plant in Parma, and corporate costs rose to €12 million from €10.7 million as the Group builds out its structure.

#million

By Mike Sheikh
Cocrystal Pharma (NASDAQ: COCP) may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of a rescue, but there is more to this story than what meets the eye. Investors glancing at the stock chart may miss the signs of a strategic reset orchestrated by biotech legends, and miss this unique opportunity.
COCP is not a company that lacks science or researchers. It has a drug discovery platform technology capable of delivering broad spectrum antivirals on demand for high value diseases that include norovirus, influenza, coronaviruses, and hepatitis C. If you had to point to something they were lacking then the missing "it factor" was a clear strategic vision. They needed an operator and a commercialization guru capable of aligning the board to his vision and raising the capital they needed on favorable terms to turn a platform technology into an enterprise.
The appointment of James Sapirstein was a transformative moment for the company.
Sapirstein is a high powered biotech exec with an impeccable pedigree. He's not an eager early-career operator looking to make a name for himself. Investors need to realize he joined after decades of experience in commercial pharmaceutical leadership, antiviral development, product launches, and business development. From his bio we learned that he has participated in or led 23 product launches and has driven numerous business-development transactions. His résumé includes founding CEO of Tobira Therapeutics, CEO of Contravir Pharmaceuticals (Hepion Pharmaceuticals, Inc. NASDAQ: HEPA), executive leadership at Serono Laboratories, senior commercial roles at Gilead Sciences (NASDAQ: GILD), and international marketing leadership in Bristol Myers Squibb's (NYSE:BMY) infectious-disease division.

#NASDAQ #Biotech

Conan O'Brien joked about having the same decorating style as President Donald Trump during a silly moment on his latest podcast.
While riffing about his beloved golden retriever on Monday's episode of "Conan O'Brien Needs a Friend," the comic said he deals with his dog's shedding habit by buying exclusively gold clothes.
Spotting an opportunity to roast the president and his famous fondness for shiny things, O'Brien said he'd even given his home the Midas touch with a metallic paint job and "all gold rugs."
President Donald Trump in his fabulously gilded Oval Office on July 21. Kevin Dietsch via Getty Images
Like this article? Keep independent journalism alive. Support HuffPost.

#Trump #friend

Gilead Sciences, Inc. (NASDAQ:GILD) delivered its strongest commercial momentum in several years during fiscal Q2 2026, with growth extending across HIV, oncology, and liver disease. Total revenue increased 10% year over year to approximately $7.8 billion, while product sales rose 8% to $7.6 billion.
Yet, the income statement tells a considerably less flattering story. Gilead (NASDAQ:GILD) reported a substantial quarterly loss after recording more than $11 billion in acquired research and development expenses. Investors may look at the earnings as a strengthening commercial business, but not without an expensive attempt to build its next generation of growth.
Gilead's (NASDAQ:GILD) underlying business performed strongly during the quarter. Product sales excluding Veklury increased 10% to $7.6 billion, demonstrating that growth was driven by the company's core portfolio rather than its declining COVID-19 treatment. HIV remained the principal contributor, with sales rising 12% to $5.7 billion. Biktarvy revenue increased 7% to $3.8 billion, while Descovy sales climbed 48% to $967 million. Yeztugo, Gilead's (NASDAQ:GILD) twice-yearly injectable HIV-prevention medicine, generated $232 million as its launch continued to gain traction.
It is significant to note that growth in the quarter was not limited to HIV. Liver-disease sales increased 10% to $877 million, supported primarily by higher demand for Livdelzi and treatments for chronic hepatitis B and hepatitis delta. Livdelzi alone generated $167 million, more than doubling year over year.
Trodelvy also strengthened Gilead's (NASDAQ:GILD) oncology case. Driven by higher demand, sales of the breast-cancer treatment increased 26% to $457 million. Although oncology remains much smaller than HIV, Trodelvy's growth provides evidence that Gilead (NASDAQ:GILD) is developing another meaningful commercial franchise. Management responded to the quarter by raising the lower end of its 2026 product-sales guidance. The company now expects 30.1–30.4 billion, compared with 30.0–30.4 billion previously. It also increased its product-sales forecast excluding Veklury to 29.8–30.1 billion, up from 29.4–29.8 billion.

#gild #increased

The next few years will test whether Pfizer Inc. (NYSE:PFE) can replace yesterday's blockbusters, and whether Gilead Sciences, Inc. (NASDAQ:GILD) can become more than an HIV company. Pfizer's (NYSE:PFE) newer medicines are gaining traction, but that growth has yet to accelerate the wider business. Gilead (NASDAQ:GILD) is expanding faster, although its performance remains concentrated in one therapeutic area. For investors, this is ultimately a choice between an unfinished turnaround and a stronger growth story still searching for greater breadth.
Pfizer's (NYSE:PFE) strongest result was the performance of its non-COVID portfolio. Revenue excluding Comirnaty and Paxlovid grew 5% operationally, while launched and acquired products generated $3.2 billion and increased 18% operationally. Growth also came from several franchises. Padcev revenue rose 23% operationally to $667 million, supported by increased market share in bladder cancer. The Vyndaqel family generated $1.76 billion, up 8% operationally, while Lorbrena grew 37% operationally. These products give Pfizer more than one avenue for rebuilding revenue as COVID-related demand declines.
Pfizer (NYSE:PFE) lowered its 2026 COVID-product forecast from approximately $5 billion to $4 billion after low infection levels weighed on Paxlovid utilization. Nevertheless, stronger-than-expected non-COVID sales allowed the company to raise the midpoint of its total revenue guidance by $500 million. Cost reductions provide additional support for the company. Pfizer (NYSE:PFE) expects approximately $6.7 billion in savings from its cost-realignment program through 2029. A separate manufacturing-optimization program is expected to generate another $3 billion, bringing anticipated savings across the two programs to approximately $9.7 billion. This leaner cost base could help Pfizer (NYSE:PFE) preserve margins and continue investing in areas such as oncology and obesity.
Gilead (NASDAQ:GILD), however, is currently delivering much stronger underlying growth. Product sales excluding Veklury increased 10% to $7.6 billion, and HIV sales rose 12% to $5.7 billion, with Biktarvy revenue increasing 7% to $3.8 billion and Descovy sales climbing 48% to $967 million. Yeztugo, Gilead's (NASDAQ:GILD) twice-yearly injectable HIV-prevention medicine, contributed $232 million as its launch gained momentum. The product adds a potentially important growth driver to an already dominant HIV portfolio.
Growth, however, was not confined to HIV alone, as liver-disease sales increased 10% to $877 million, while Livdelzi revenue more than doubled from $78 million to $167 million. Trodelvy sales rose 26% to $457 million, providing further evidence that Gilead (NASDAQ:GILD) is building a meaningful oncology franchise. Management subsequently raised its 2026 product-sales outlook to $30.1–$30.4 billion and increased guidance for product sales excluding Veklury to $29.8–$30.1 billion.

#NYSE #million #gild

Gilead Sciences, Inc. (NASDAQ:GILD) delivered its strongest commercial momentum in several years during fiscal Q2 2026, with growth extending across HIV, oncology, and liver disease. Total revenue increased 10% year over year to approximately $7.8 billion, while product sales rose 8% to $7.6 billion.
Yet, the income statement tells a considerably less flattering story. Gilead (NASDAQ:GILD) reported a substantial quarterly loss after recording more than $11 billion in acquired research and development expenses. Investors may look at the earnings as a strengthening commercial business, but not without an expensive attempt to build its next generation of growth.
Gilead's (NASDAQ:GILD) underlying business performed strongly during the quarter. Product sales excluding Veklury increased 10% to $7.6 billion, demonstrating that growth was driven by the company's core portfolio rather than its declining COVID-19 treatment. HIV remained the principal contributor, with sales rising 12% to $5.7 billion. Biktarvy revenue increased 7% to $3.8 billion, while Descovy sales climbed 48% to $967 million. Yeztugo, Gilead's (NASDAQ:GILD) twice-yearly injectable HIV-prevention medicine, generated $232 million as its launch continued to gain traction.
It is significant to note that growth in the quarter was not limited to HIV. Liver-disease sales increased 10% to $877 million, supported primarily by higher demand for Livdelzi and treatments for chronic hepatitis B and hepatitis delta. Livdelzi alone generated $167 million, more than doubling year over year.
Trodelvy also strengthened Gilead's (NASDAQ:GILD) oncology case. Driven by higher demand, sales of the breast-cancer treatment increased 26% to $457 million. Although oncology remains much smaller than HIV, Trodelvy's growth provides evidence that Gilead (NASDAQ:GILD) is developing another meaningful commercial franchise. Management responded to the quarter by raising the lower end of its 2026 product-sales guidance. The company now expects 30.1–30.4 billion, compared with 30.0–30.4 billion previously. It also increased its product-sales forecast excluding Veklury to 29.8–30.1 billion, up from 29.4–29.8 billion.

#product

WASHINGTON (AP) — Instead of adding new roses, President Donald Trump's White House Rose Garden is growing statues.
Trump put statues of some of America's founders in the garden just off the Oval Office after he replaced its plush lawn with a white stone patio, turning the historic outdoor **** e into a look-alike of the one at his Mar-a-Lago home and private club in Palm Beach, Florida.
At least one statue was a gift. Others are on loan from people who wish to remain anonymous.
The latest addition, a bronze depiction of a seated Thomas Jefferson signing the Declaration of Independence, was a gift from George Lundeen, a sculptor from Loveland, Colorado. It joins statues already displayed there of George Washington, Alexander Hamilton and Ben Franklin. A fifth sculpture named "Freedom's Charge" is also on the patio.
The statues are part of Trump's sweeping series of White House renovations, from his gilded makeover of the Oval Office to the ballroom and helipad that the Republican president is having built on the south grounds. These projects fit into Trump's broader plan to leave his mark on downtown Washington through other construction projects, including a statue garden on federal land near the National Mall.

#House

Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn't always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this year, their recent double dose of clinical and regulatory breakthroughs across oncology and virology shows how strategic alliances can reshape two massive therapeutic markets at once.
Merck & Co., Inc. delivered $16.3 billion in total sales for the first quarter of 2026, up 5% year-over-year (3% excluding foreign exchange). Top-line growth continued to be anchored by its flagship oncology therapy, Keytruda, which, alongside its sub-formulations, brought in $8.0 billion in sales, representing an 8% ex-exchange increase. Pulmonary arterial hypertension treatment Winrevair also contributed strongly with $525 million in quarterly revenue, up 87% ex-exchange. GAAP and non-GAAP bottom-line metrics reflected net losses per share of $1.72 and $1.28, respectively, largely driven by upfront charges tied to the strategic acquisition of Cidara Therapeutics. Despite those acquisition-related charges, Merck narrowed and raised the midpoint of its full-year worldwide sales guidance to between $65.8 billion and $67.0 billion.
Merck's growth story remains heavily reliant on expanding Keytruda's reach into earlier-stage treatments and novel combination regimens. With key patent expirations approaching toward the end of the decade, management has aggressively pursued business development and combination therapies to diversify its revenue base and maintain its dominance in immuno-oncology.
Gilead Sciences, Inc. reported $7.0 billion in total revenue for the first quarter of 2026, posting 5% year-over-year product sales growth. Gilead's base business, excluding COVID-19 treatment Veklury, rose 8% year-over-year to $6.8 billion, powered by its market-leading HIV franchise, which generated $5.0 billion in sales (up 10% year-over-year). Biktarvy remained the primary growth driver, while newly launched therapies like Yeztugo (lenacapavir) for HIV pre-exposure prophylaxis provided fresh momentum. The corporation's adjusted diluted earnings per share reached $2.03.
Backed by strong demand across its core virology portfolio, Gilead Sciences, Inc. raised its full-year 2026 total product sales guidance range by $400 million, targeting $30.0 billion to $30.4 billion.

#billion #merck #sciences #oncology

During the top of the third inning of Monday night's Royals vs. Dodgers game, the SportsNet LA broadcast flashed a leaderboard of the lowest starter ERA since the start of the 2023 season. Of the five names listed, four are currently employed by the back-to-back champs: Yoshinobu Yamamoto, Shohei Ohtani, Blake Snell and the star of this particular evening, Tarik Skubal. Some understandably pessimistic fans in western Pennsylvania surely harbor fear that the fifth figure, Paul Skenes, will end up in Dodger blue one day as well.
But if that list was a reminder — as if anybody needed another — of the preposterous talent gilding L.A.'s star-studded roster, Skubal's ordinary performance on Monday in his first home start as a Dodger emphasized that nothing in this wonky sport is preordained.
Pitching in front of a revved up, eager audience, Skubal was downright mediocre in L.A.'s 6-5 victory over the Royals.
His fastball command was, by his cathedral standards, scattershot. He struggled to locate the four-seamer consistently at and just above the top rail, right where the world-beating southpaw makes his bread. Skubal had similar issues with his sinker, a handful of which ended up catching far too much plate, including one that resulted in a first-inning RBI single from Royals first baseman Jac Caglianone.
But the hammer blow of Skubal's night came in the third, when he gifted Caglianone a hanging, piped 0-2 slider. The scalding-hot lefty didn't miss the miss, sizzling the breaker 110.8 mph into the right-field seats to give Kansas City an early 3-0 lead.

#four

During the top of the third inning of Monday night's Royals vs. Dodgers game, the SportsNet LA broadcast flashed a leaderboard of the lowest starter ERA since the start of the 2023 season. Of the five names listed, four are currently employed by the back-to-back champs: Yoshinobu Yamamoto, Shohei Ohtani, Blake Snell and the star of this particular evening, Tarik Skubal. Some understandably pessimistic fans in western Pennsylvania surely harbor fear that the fifth figure, Paul Skenes, will end up in Dodger blue one day as well.
But if that list was a reminder — as if anybody needed another — of the preposterous talent gilding L.A.'s star-studded roster, Skubal's ordinary performance on Monday in his first home start as a Dodger emphasized that nothing in this wonky sport is preordained.
Pitching in front of a revved up, eager audience, Skubal was downright mediocre in L.A.'s 6-5 victory over the Royals.
His fastball command was, by his cathedral standards, scattershot. He struggled to locate the four-seamer consistently at and just above the top rail, right where the world-beating southpaw makes his bread. Skubal had similar issues with his sinker, a handful of which ended up catching far too much plate, including one that resulted in a first-inning RBI single from Royals first baseman Jac Caglianone.
But the hammer blow of Skubal's night came in the third, when he gifted Caglianone a hanging, piped 0-2 slider. The scalding-hot lefty didn't miss the miss, sizzling the breaker 110.8 mph into the right-field seats to give Kansas City an early 3-0 lead.

#Royals #caglianone #inning #start

Amanda Knox is taking her story to a comedy stage in Edinburgh, nearly two decades after the murder of her roommate Meredith Kercher thrust her into an international media frenzy.
Knox made her Edinburgh Fringe debut with her show "Cartwheel," a one-woman show that blends comedy and storytelling as she reflects on her wrongful conviction, years in an Italian prison and the challenge of explaining her past to her young daughter.
The show, which began its Edinburgh run Aug. 7, and is scheduled through Aug. 17 at Gilded Balloon, is already sold out. The show takes its name from one of the most infamous narratives to emerge during the investigation into Kercher's death, which claimed that Knox performed cartwheels at an Italian police station.
Amanda Knox: 'Twisted Tale' asks, 'in the wake of trauma, how do you rebuild your life?'
The show has reignited the controversy surrounding the 2007 murder of Kercher, with members of the British student's family criticizing Knox decision to revisit the case through comedy.

#edinburgh #kercher #murder #fringe

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, the Fund appreciated 10.61% on an annualized basis, compared with 10.02% for the Benchmark and 14.83% for the Index. Strong stock selection in pharmaceuticals, biotechnology, health care equipment, and life sciences tools and services supported the Fund's outperformance, although limited exposure to managed care stocks reduced relative returns. The Fund remains positive on health care due to improving biotechnology funding, strong acquisition activity, recovering managed care margins, and growth from an aging population, chronic disease, medical innovation, and higher health care spending. In addition, please check the Fund's top five holdings to know the best picks in 2026.
In its second-quarter 2026 investor letter, Baron Health Care Fund highlighted Gilead Sciences, Inc. (NASDAQ:GILD). Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company that discovers, develops, and commercializes medicines for unmet medical needs, detracted from the fund's performance during the quarter. On August 03, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) closed at $131.15 per share. The one-month return of Gilead Sciences, Inc. (NASDAQ:GILD) was -3.82%, and its shares gained 16.62% over the past 52 weeks. Gilead Sciences, Inc. (NASDAQ:GILD) has a market capitalization of $162.83 billion.
Baron Health Care Fund stated the following regarding Gilead Sciences, Inc. (NASDAQ:GILD) in its Q2 2026 investor letter:
"Biotechnology company Gilead Sciences, Inc. (NASDAQ:GILD) is best known for developing and commercializing therapies that treat and prevent HIV. Following a strong first-quarter advance driven by continued enthusiasm surrounding the launch of Yeztugo for HIV prevention, the stock detracted from performance in the second quarter. Shares pulled back after management issued conservative 2026 guidance in February, including expectations for approximately $800 million of Yeztugo sales, below investor expectations. Despite the more cautious outlook, we remain confident in Yeztugo's long-term opportunity. Unlike Descovy, a daily oral preventive treatment, Yeztugo is a twice-yearly injectable therapy that has the potential to significantly improve patient compliance. Looking ahead, we continue to view Gilead as a leader in HIV treatment and prevention, with Yeztugo representing an important new preventive option and a promising next-generation pipeline that includes a weekly oral lenacapavir and islatravir combination being developed with Merck & Co., Inc., as well as a wholly-owned weekly regimen incorporating a novel integrase inhibitor designed to offer a higher barrier to resistance."

#sciences #gild #Health

Last week's bombshell federal order granting high school class of 2022 athletes a fifth season of eligibility is already producing widespread ripple effects through college basketball. Hundreds of graduating seniors are doing an about-face and returning to the college level for one more year, including former St. John's guard Oziyah Sellers, who entered the transfer portal on Saturday. Another Red Storm senior could join him soon.
Dillon Mitchell, the former St. John's forward and Boston Celtics rookie, could return to the program this upcoming season, according to Adam Zagoria. The Red Storm are also reportedly interested in Auburn forward and All-SEC selection Keyshawn Hall, another senior eyeing a fifth season in college basketball.
Mitchell was selected with the 40th overall pick in the 2026 NBA draft by the Boston Celtics and stood out in the NBA Summer League, averaging 13.0 points and 5.0 rebounds on solid shooting efficiency in three games. Yet, he remains unsigned by the team, meaning he is still eligible to return to college basketball if he can't agree to terms with the Celtics.
His pathway to a possible comeback is clear after forward Gildas Gimenez was reportedly deemed academically ineligible, opening up a spot on the 15-man roster if Mitchell opts to go back to college.
The ultra-athletic 6-foot-8 forward transferred to St. John's following stops at Texas and Cincinnati, quickly forming a three-headed monster with fellow All-Big East honorees Zuby Ejiofor and Bryce Hopkins. Last season, Mitchell averaged 8.3 points, 7.0 rebounds, and 3.0 ***** ists on 55.9% shooting for the Red Storm and also earned a spot on the Big East All-Defense team after posting 1.3 steals and 0.7 blocks per game for a KenPom top-15 defensive unit.

#college #storm

Sean Astin is looking back on a "traumatic" experience brought on by his famous mom, Patty Duke.
While on a set as a teenage actor, Astin says Duke "flipped out" on a crew member who made a "disparaging" comment about his braces.
"She was only 4 feet 11 inches, but she scared the s--- out of people," Astin joked.
Growing up in a Hollywood dynasty isn't all wine and roses.
Lord of the Rings alum and current SAG-AFTRA president Sean Astin learned that lesson the hard way, coming up under the gilded wing of Hollywood legend Patty Duke.

#duke #lord

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need. Valued at $166.7 billion by market cap, the company's primary areas of focus include HIV, AIDS, liver disease, and serious cardiovascular and respiratory conditions. The HIV giant is expected to announce its fiscal second-quarter earnings for 2026 in the near term.
Ahead of the event, ******* ysts expect GILD to report a loss of $7.09 per share on a diluted basis, down 452.7% from a profit of $2.01 per share in the year-ago quarter. The company has consistently surpassed the consensus estimates in each of the last four quarters.
Huge, Unusual Intel Options Volume Today Ahead of Earnings This Week
Intel Stock Is Down, But Put Premiums are High - Put Short Sellers Love the High Yields
The Number Tesla Stock Bulls Are Really Waiting for This Earnings Season Has Nothing to Do With Cars

#earnings

WASHINGTON (AP) — President Donald Trump's plans to build a skyline-altering arch in the nation's capital is getting another review from the federal commission whose approval he needs, but the agency's staff says the project should be revised before it gets the go-ahead.
The National Capital Planning Commission is meeting Thursday, and the Republican president's proposed 250-foot (76-meter) arch is one of the items on the agenda.
In a report, the agency's staff recommends that the commission approve the preliminary site and building plans for the arch. But the staff also recommends that the design be tweaked to comply with a federal law that limits building heights in downtown Washington to preserve the city's famous skyline. The planning commission applies the law during its approval process.
"Staff suggests the Commission request the applicant revise the project design to comply with the Height of Buildings Act and return to NCPC for final approval," the 185-page report says.
Applying the law "would require design revisions to redistribute the height between the main structure, habitable roof structure and statuary," the report said. But even with the recommended revisions, the arch, a public observation deck and three gilded topper statues would still reach Trump's desired 250-foot height, the report said.

WASHINGTON (AP) — President Donald Trump's plans to build a skyline-altering arch in the nation's capital is getting another review from the federal commission whose approval he needs, but the agency's staff says the project should be revised before it gets the go-ahead.
The National Capital Planning Commission is meeting Thursday, and the Republican president's proposed 250-foot (76-meter) arch is one of the items on the agenda.
In a report, the agency's staff recommends that the commission approve the preliminary site and building plans for the arch. But the staff also recommends that the design be tweaked to comply with a federal law that limits building heights in downtown Washington to preserve the city's famous skyline. The planning commission applies the law during its approval process.
"Staff suggests the Commission request the applicant revise the project design to comply with the Height of Buildings Act and return to NCPC for final approval," the 185-page report says.
Applying the law "would require design revisions to redistribute the height between the main structure, habitable roof structure and statuary," the report said. But even with the recommended revisions, the arch, a public observation deck and three gilded topper statues would still reach Trump's desired 250-foot height, the report said.

Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.'s share was trading at $133.73 as of May 26th. GILD’s trailing and forward P/E were 18.19 and 15.22 respectively according to Yahoo Finance.
Pressmaster/Shutterstock.com
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States and internationally. GILD is being mischaracterized by the market as a slow-growth HIV cash cow despite a rapidly shifting pipeline that increasingly skews toward long-acting HIV innovation and a credible oncology expansion, suggesting the current valuation underappreciates its multi-platform earnings durability.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls' thesis on GILD. Gilead Sciences, Inc.'s share was trading at $133.73 as of May 26th. GILD's trailing and forward P/E were 18.19 and 15.22 respectively according to Yahoo Finance.
Pressmaster/Shutterstock.com
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States and internationally. GILD is being mischaracterized by the market as a slow-growth HIV cash cow despite a rapidly shifting pipeline that increasingly skews toward long-acting HIV innovation and a credible oncology expansion, suggesting the current valuation underappreciates its multi-platform earnings durability.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best inexpensive stocks to invest in right now. Gilead Sciences, Inc. (NASDAQ:GILD) announced on May 27 new results from a post hoc ***** ysis that showed that Livdelzi® was ***** ociated with high and sustained rates of normalization of a key liver marker in people living with primary biliary cholangitis. The company reported that participants with increased ALP levels in an ongoing Phase 3 study experienced reductions in ALP after treatment, and the data showcase the potential role of Livdelzi in people with PBC who continually have elevated ALP despite prior treatment with first-line therapy.
Gilead Sciences, Inc. (NASDAQ:GILD) stated that the findings are “highly relevant” for people living with PBC with inadequately controlled disease based on elevated ALP levels, as that is a population that is historically underrepresented in randomized clinical trials. The company would present the data at the European ***** ociation for the Study of the Liver (EASL) Congress 2026, held May 27–30 in Barcelona, Spain.
Gilead Sciences, Inc. (NASDAQ:GILD) is a biotech company that advances medicines to prevent and treat serious diseases such as cancer, immunodeficiency virus (HIV), viral hepatitis, and COVID-19. Its portfolio of drugs focuses on medical areas with unmet needs and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others.
While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.